Drug Trial Radar · NCT06299098
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,005
Actual
Start
Mar 13, 2024
Primary completion
Jun 16, 2026
Study completion Oct 21, 2026
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Mar 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®). This study will be done in 3 parts, Part A, Part B, and Part C where different study drugs will be tested. Part A of the study is focused on healthy participants. Part B and C of the study is focused on participants with obesity. The aim of Part A of the study is to see how safe and tolerable the study drug is in healthy participants. The aim of Part B and Part C of the study is to see how safe and effective the study drug is when combined with Wegovy. Parts A, B, and C of the study are looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Conditions
- Obesity
Interventions
Trevogrumab-Part ADrug
Administered IV or SC in Part A
Trevogrumab-Part B and Part CDrug
Administered SC in Part B, Part C
GaretosmabDrug
Administered IV in Part B
SemaglutideDrug
Administered SC in Part B and Part C
Matching Placebo-Part ADrug
Administered IV or SC in Part A
Matching Placebo-TrevogrumabDrug
Administered SC in Part B and Part C
Matching Placebo-GaretosmabDrug
Administered IV in Part B
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs)Time frame: Baseline to week 7
- Severity of TEAEsTime frame: Baseline to week 7
- Percent change in total fat massTime frame: Baseline to week 26
- Percent change in total lean massTime frame: Baseline to week 26
- Percent change in body weightTime frame: Baseline to week 26
- Percent change in total fat massTime frame: Baseline to week 52
- Percent change in total lean massTime frame: Baseline to week 52
- Percent change in body weightTime frame: Baseline to week 52
Locations
60 sites in 2 countries. Site status is shown where the registry gives one.
Pinnacle Research Group
Anniston, Alabama
Cullman Clinical Trials
Cullman, Alabama
Foothills Research Center Cct Research
Phoenix, Arizona
Anaheim Clinical Trials
Anaheim, California
ProSciento
Chula Vista, California
Valiance Clinical Research- Huntington Park
Huntington Park, California
Velocity, San Diego
La Mesa, California
Northern California Research
Sacramento, California
Acclaim Clinical Research
San Diego, California
Metabolic Institute of America
Tarzana, California
Valiance Clinical Research
Tarzana, California
Southwest General Healthcare Center
Fort Myers, Florida
Westside Center for Clinical Research
Jacksonville, Florida
Jacksonville Center for Clinical Research
Jacksonville, Florida
IMA Clinical Research St. Petersburg
St. Petersburg, Florida
Precision Clinical Research, LLC
Sunrise, Florida
Clinical Research of West Florida, Inc.
Tampa, Florida
Clinical Research of Central Florida - Bond Clinic
Winter Haven, Florida
Center for Advanced Research and Education
Gainesville, Georgia
Balanced Life Health Care Solutions
Lawrenceville, Georgia
North Georgia Clinical Research
Woodstock, Georgia
East-West Medical Research Institute
Honolulu, Hawaii
Elite Clinical Trials LLLP
Blackfoot, Idaho
Prairie Education and Research Cooperative (PERC)
Springfield, Illinois
The South Bend Clinic Center for Research
South Bend, Indiana
Cotton O'Neil Clinical Research Center
Topeka, Kansas
L-MARC Research Center
Louisville, Kentucky
Tandem Clinical Research GI, LLC
Marrero, Louisiana
IMA Clinical Research Monroe - Armand
Monroe, Louisiana
Mayo Clinic
Rochester, Minnesota
Prime Health and Wellness Clinic
Fayette, Mississippi
Olive Branch Family Medical Center
Olive Branch, Mississippi
Sky Integrative Medical Center Skycrng
Ridgeland, Mississippi
Jefferson City Medical Group
Jefferson City, Missouri
Clinvest Research
Springfield, Missouri
Mercury Street Medical Group, PLLC
Butte, Montana
Hassman Research Institute
Berlin, New Jersey
Accellacare Clinical Research, Raleigh Medical Group
Raleigh, North Carolina
Accellacare of Salisbury
Salisbury, North Carolina
Accellacare of Piedmont, Piedmont Healthcare
Statesville, North Carolina
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.